title: Hemodialysis-associated induction of cytokines.
abstract: The interleukin hypothesis relates chronic pathology in long-term end-stage renal disease (ESRD) patients to repeated stimulation of mononuclear cell cytokine production during hemodialysis. In vitro experiments demonstrated different possible mechanisms involved in hemodialysis-associated cytokine induction: adherence of mononuclear cells to the dialyzer membrane; complement activation, and the passage of cytokine-inducing bacterial fragments from contaminated dialysate through the dialyzer membrane into the blood. Studies investigating mononuclear cells from ESRD patients ex vivo suggest that these cells become activated during hemodialysis with complement-activating membranes and that the type of dialyzer membrane may influence mononuclear cell cytokine production in response to endotoxin. According to biological assays, plasma levels of interleukin-1 but not interleukin-6 activity seem to be elevated in ESRD patients compared to normal subjects and may increase further during treatment depending on the choice of the dialyzer membrane. However, to date, partly due to insufficient assay sensitivity and circulating inhibitors, measurements of interleukin-1, interleukin-6 and tumor necrosis factor in plasma by specific immunoassays could not finally prove elevated plasma cytokine levels in ESRD patients. Since circulating mononuclear cells are a major source of cytokines, studying the activation of these cells ex vivo seems to be the best approach to study hemodialysis-associated cytokine induction.
authors.affiliation: Abteilung Nephrologie, Medizinische Hochschule Hannover, BRD.
authors.forename: G
authors.initials: G
authors.lastname: Lonnemann
authors.forename: M
authors.initials: M
authors.lastname: Haubitz
authors.forename: R
authors.initials: R
authors.lastname: Schindler
mesh_terms: D016207:Cytokines / Q000096:biosynthesis* / Q000097:blood; D005786:Gene Expression Regulation; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000628:therapy; D007963:Leukocytes, Mononuclear / Q000378:metabolism; D008567:Membranes, Artificial; D006435:Renal Dialysis / Q000009:adverse effects* / Q000295:instrumentation
chemical_list: D016207:Cytokines; D008567:Membranes, Artificial